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 Summary 
The proficiency test for antibiotics in beef was organized by Rikilt - Institute of Food Safety and in 
accordance with ISO/IEC Guide 43-1 and 43-2 and ILAC-G13. The quantitative and confirmatory part 
was carried out under accreditation (Dutch Accreditation Board, ILAC-G13). 
 
For this proficiency study, three test materials were prepared: 
• a blank beef material; 
• a beef material containing flumequine aimed at 280 µg/kg; 
• a beef material containing lincomycin aimed at 120 µg/kg and spectinomycin aimed at 230 µg/kg. 
The materials containing antibiotics were all prepared by spiking blank beef materials. During 
homogeneity testing, all materials proved to be sufficient homogenous for proficiency testing. The 
stability test demonstrated that no statistically significant loss of any of the compounds occurred during 
the timescale of the proficiency test. 
 
The laboratories were asked to first carry out a screening analysis followed by a quantitative 
confirmatory analysis for the compounds found suspected. Twenty-six laboratories subscribed for 
participation in the proficiency study. Within the timeframe of the stability study all laboratories 
submitted results: 23 laboratories managed to submit results for the screening analysis and 19 for the 
quantitative confirmatory part. 
 
Seven laboratories did not detect any antibiotics using their screening methodology. Nine laboratories 
characterized the samples correctly (compliant or suspect) based on the screening analysis and only 
three laboratories indicated the correct compound groups for all materials. It is stated that these three 
laboratories carried out several parallel LC-MS/MS methods as the screening approach.  
 
An overview of the screening analysis results is presented in Table 1. A result is considered to be a false 
negative result if a compound present in the sample is not detected although it is included in the method. 
If each compound is considered separately, the false negative rate of the screening analyses is 53%. For 
microbiological methods the overall false negative rate is 73%, for biochemical methods this is 50% and 
for instrumental analysis this is 22%. The false positive rate is 7% which is due to microbiological 
screening methods only.  
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 Table 1. Overview of correct, false negative and false positive results for microbiolocical, biochemical and 
instrumental methods.  
Material A B C 
Compounds  Flumequine Lincomycin Spectinomycin 
No. of methods applied*  23 24 17 
Correct results  15 9 6 
     Microbiology methods  4 4 2** 
     Biochemical methods  2 - - 
     Instrumental methods  9 5 4 
False negatives   8 15 11 
     Microbiology methods  7 10 10 
     Biochemical methods  - 2 - 
     Instrumental methods  1 3 1 
False positives 3 1# - - 
* Because some laboratories applied several different methods and some laboratories do not have all compounds 
relevant for this proficiency test included in their method, this number is different from the number of 
laboratories. 
** Only growth inhibition was reported (no antibiotic group specified). 
# Found suspect for containing macrolides 
Regarding the applied methods it is concluded that: 
• the applied microbiological screening methods showed 73% of false negative results; 
• many combination of screening tests are used to cover the broad range of antibiotic groups; 
• the Nouws Antibiotic Test is the only microbiological test that correctly assigned material A 
negative and material B and C suspect. 
• microbiological and biochemical methods do not seem capable of detecting spectinomycin at a 
relevant level.  
 
Seventeen laboratories carried out a quantitative confirmatory analysis for quinolones, seven for 
macrolides and four for aminoglycosides. No false negatives occurred during the confirmatory analysis. 
One laboratory detected 25 µg/kg sulfamethazin in one of the samples which is considered as a false 
positive result. For the quantitive confirmatory analysis of flumequine and lincomycin all laboratories 
obtained satisfactory z-scores. No statistical evaluation is carried out for spectinomycin because only 
four results are reported. 
 
Based on the results of this proficiency test it is concluded that: 
• a huge effort is needed to improve the effectiveness and efficiency for the screening of veterinary 
drugs in muscle samples; 
• a huge effort is needed to decrease the false negative rate of microbiological screening methods; 
• for effectively applying instrumental screening methods (LC-MS/MS or LC-ToF MS) effort is 
needed to include a wider range of compounds; 
• the performance of all laboratories regarding the quantitative analysis of flumequine and lincomycin 
in beef is satisfactory. 
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 1 Introduction 
Proficiency testing is conducted to provide laboratories with a powerful tool to evaluate and 
demonstrate the reliability of the data that is produced. Next to validation and accreditation, proficiency 
testing is an important requirement of the EU Additional Measures Directive 93/99/EEC [1] and is 
demanded by ISO 17025:2005 [2].  
 
No internationally focused broad range proficiency studies regarding the analysis of antibiotics in 
bovine muscle that focused on the screening analysis and the quantitative and confirmatory aspect were 
organized during the last years: an inter-laboratory quality control that combines screening and 
confirmatory methods of this type was lacking. Therefore, Rikilt decided to organize a proficiency study 
regarding this subject.  
 
The aim of this proficiency study was to give laboratories the possibility to evaluate or demonstrate 
their competence for the analysis of antibiotics in bovine tissues, including the screening analysis. This 
study also provided an evaluation of the methods applied for screening and quantitative and 
confirmatory analysis of antibiotics in beef.  
 
This proficiency study was conducted in accordance with guidelines ISO/IEC 43-1 [3], ISO/IEC 43-2 
[4] and ILAC-G13 [5]. The preparation of the materials, including the suitability testing of the materials 
and the evaluation of the quantitative and confirmatory results were carried out under accreditation by 
Rikilt - Institute of Food Safety. 
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 2 Test materials 
This proficiency study focused on flumequine (a quinolone) and the combination of lincomycin (a 
lincosamide, closely related to macrolides) and spectinomycin (an aminoglycoside). The maximum 
residue limits (MRLs) for these compounds in beef are presented in Table 2.  
Table 2. MRL in bovine muscle of the compounds included in the proficiency test [6] 
Compound MRL in beef (µg/kg) 
Flumequine 200 
Lincomycin 100 
Spectinomycin 300 
2.1 Sample preparation 
One blank material (A), one material (B) containing flumequine (FLU) and one material (C) containing 
a combination of lincomycin (LMC) and spectinomycin (SMC). Material B and C were prepared by 
adding methanolic solutions of the selected compounds to blank bovine muscle. We aimed at the levels 
as presented in Table 3. Each of the materials was homogenized under cryogenic conditions according 
to in-house standard operating procedures. 
Table 3. Target amount of antibiotics in the proficiency test materials  
Target amount (µg/kg)  
Material code 
FLU LMC SMC 
A - - - 
B 280 - - 
C - 120 230 
2.2 Sample identification 
The materials were stored in polypropylene containers containing at least 75 gram of sample, yielding a 
total of 42 containers of material A and 98 containers of material B and C. The samples were randomly 
coded with a code from AB1/2009/MUSCLE/001 through 238.  
 
For homogeneity and stability testing, 20 randomly selected containers of material B and C were 
assigned. For each laboratory a sample set was prepared consisting of one randomly selected sample of 
material A, B and C. The codes of the samples belonging to each sample set are presented in Annex 1. 
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 2.3 Homogeneity study 
The homogeneity of the materials was tested according to The International Harmonized Protocol for 
Proficiency Testing of Analytical Laboratories [7] and ISO/DIS 13528 [8], taking into account the 
insights discussed by Thompson [9] regarding the Horwitz equation. With this procedure the between-
sample standard deviation ( ) is compared with the target  standard deviation derived from the 
Horwitz equation ( , §4.2.3). A material is considered adequately homogeneous if . 
ss
Hσ Hs σ3.0s ≤
 
Ten containers of materials B were analyzed in duplicate for flumequine and ten containers of sample C 
were analyzed in duplicate for lincomycin and spectinomycin to determine the homogeneity of the 
materials. The results of the homogeneity study and their statistical evaluation are presented in Annex 
2a through c. All materials demonstrated to be sufficiently homogeneous for use in the proficiency 
study. The amounts determined during the homogeneity study are presented in table 3. 
 
No extensive homogeneity study was carried out for material A. The homogeneity of these materials is 
not relevant because the results of these materials will not be evaluated in a quantitative way. 
Furthermore, it is assumed that the homogeneity of material A is comparable to the homogeneity of the 
other materials because all materials are homogenized in the same way. Nevertheless, three randomly 
selected samples of material A were analyzed for quinolones, macrolides and aminoglycosides. None of 
these antibiotics were detected. It was concluded that material A is suitable to use as blank materials in 
the proficiency study. 
2.4 Participants 
Twenty-six laboratories subscribed for participation in the proficiency study antibiotics in beef of which 
25 are situated within Europe. Twenty-three laboratories indicated to carry out a screening analysis. 
Twenty-two laboratories indicated to have a quantitative confirmatory method operational for 
quinolones, 17 for macrolides and 11 for aminoglycoside.  
2.5 Sample distribution 
Each of the participating laboratories received a randomly assigned laboratory code (1 through 26). The 
sample sets with the corresponding number, consisting of three coded samples (Annex 1) were sent to 
the participating laboratories at May 27th, 2009. The sample sets were packed in an insulating box 
containing dry ice or cool packs and were dispatched to the participants immediately by courier. One 
laboratory (laboratory 16) reported that the samples were not sufficiently frozen at arrival. This 
laboratory indicated to only carry out a screening analysis and no quantitative analysis and therefore it 
was decided that the samples were still suited for the laboratory's goal. All other laboratories confirmed 
the receipt of the samples in good condition (frozen). The samples were accompanied by a letter (Annex 
3) describing the requested analyses, an acknowledgement of receipt form and a results form.  
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 The laboratories were asked to store the samples until analysis according to their own laboratory’s 
procedure. A single analysis of each sample was requested, resulting in one results for materials A, B 
and C. The deadline for sending in results was August 1st 2009, allowing the participants at least 9 
weeks for analysis. 
2.6 Stability 
Just after preparation of the materials six randomly selected samples of each material were stored at <-
70 °C. It is assumed that the antibiotics included in this proficiency test are stable at these storage 
conditions. The remaining samples were stored at -20 °C. Of these, six at random selected samples were 
subjected to a thaw-freeze cycles to verify if thawing and freezing samples, as is likely to occur when a 
screening and confirmatory analysis is carried out, does not affect the stability. 
 
At May 6th two sets of six samples were selected and stored at <-70°C. In the morning of July 29th two 
sets of six samples were selected from the samples stored at -20°C and thawed. After four hours at room 
temperature these samples were again stored at -20°C. On August 11th, eleven days after the deadline of 
the proficiency test, six samples that had been stored at -20°C, six samples that were subjected to a 
thaw-freeze cycle and six samples that had been stored at <-70°C were analyzed for flumequine, 
lincomycin and spectinomycin. For each set of samples, the average of the results and the standard 
deviation was calculated.  
 
First it was determined if a consequential instability occurred [7, 8]. A consequential instability occurs 
when the average value of the samples stored at -20°C or the samples subjected to the thaw-freeze cycle 
is more than 0.3σH below the average value of the samples stored at <-70 °C. If so, the instability has a 
significant influence on the calculated z-scores. Second, it was determined if a statistically significant 
instability occurred using a Students t-test [8]. The results and statistical evaluation of the stability test 
are presented in Annex 4.  
 
For flumequine no consequential nor a statisitical significant difference was observed between the 
samples stored at <-70°C and the samples stored at -20°C. The samples subjected to a thaw-freeze cycle 
resulted in an average that is higher than the average of the samples stored at <-70°C. Because this 
difference is not statistical significant, it is attributed to a random variation in the analytical method.  
 
For lincomycin no consequential nor a statisitical significant difference was observed between the 
samples stored at <-70°C, the samples stored at -20°C and the samples that were subjected to a thaw-
freeze cycle. The samples are considered sufficiently stable. 
 
For spectinomycin no consequential nor a statisitical significant difference was observed between the 
samples stored at <-70°C and the samples subjected to a thaw-freeze cycle. The samples stored at -20°C 
resulted in an average that is below the average of the samples stored at <-70°C. This results in a 
consequential difference, however this difference is not statistically significant. Surprisingly, the 
samples subjected to a thaw-freeze cycle result in better stability than the samples stored at -20°C. 
Therefore it is assumed that the instability is a result of random error of the applied analytical method. 
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 3 Applied methods of analysis 
The participating laboratories applied biological, biochemical or instrumental methods or a combination 
of these methods for screening analysis. An overview of applied screening methods is presented in 
Annex 5. Eleven laboratories applied a plate test ranging from four to six plates among which two 
laboratories applied the Nouws Antibiotic Test (NAT). Three laboratories applied the Premi-Test (one 
preceding a solvent extraction) either or not in combination with other microbiological, biochemical or 
instrumental methods. Three laboratories applied biochemical methods among which the Charm II 
methodology. Eleven laboratories applied an instrumental method (LC-MS/MS, LC-ToF MS, LC-FLD 
or LC-DAD) for the screening analysis. 
 
Eighteen laboratories carried out one or more confirmatory analyses. The substance groups for which a 
confirmatory analysis was carried out were either selected based on the screening results or carried out 
as an additional control. An overview of quantitative confirmatory methods applied and the compounds 
included in the methods is presented in Annex 6a. 
 
For the quantitative and confirmatory analysis of flumequine in beef several different methods are 
applied. An overview of the applied confirmatory analyses is presented in Annex 6b. For the analysis of 
flumequine in beef tissue many different extraction solvents or mixtures of solvents were used. For the 
sample clean up also several different techniques were applied: five laboratories applied solid phase 
extraction using either the reversed phase or ion exchange principle. Two laboratories use liquid-liquid 
extraction to clean up their raw extract. The other laboratories filter their extract before injection or 
inject the raw extract without further clean-up. Three main detection techniques were applied for the 
quantitative analysis of flumequine in beef: five laboratories applied LC combined with fluorescence 
(FLD) and/or diode array detection (DAD), nine laboratories used MS/MS as the detection technique 
and one laboratory applied ToF/MS. 
 
Of the participants that used mass spectrometric detection, nine used an internal standard for the 
quantification of flumequine. The internal standards used are: 
• Cincophen; 
• Norfloxacin; 
• Norfloxacin-d5; 
• Ciprofloxacin-d8; 
• 13C3-flumequine; 
• Carbendazim-d4. 
 
The methods applied for the analysis of lincomycin and spectinomycin are not presented, because only a 
limited number of laboratories reported information regarding these methods.. 
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 4 Statistical evaluation 
The evaluation of the screening and quantitative analysis are carried out separately. The screening 
analysis is evaluated in a qualitative way resulting in a false negative and false positive rate [10]. The 
statistical evaluation of the quantitative part of the study was carried out according to the International 
Harmonized Protocol for the Proficiency Testing of Analytical Laboratories [7], elaborated by ISO, 
IUPAC and AOAC and ISO/DIS 13528 [8] in combination with the insights published by the Analytical 
Methods Committee [11, 12] regarding robust statistics. 
4.1 Screening analysis 
First, all laboratories were evaluated separately regarding the screening results in which the number of 
false positives and false negatives is determined for each laboratory. The number of false positives is the 
number of samples in which growth inhibition was detected although no antibiotic was present. A result 
is assigned as false negative if an antibiotic present is not detected although it is included in the method. 
It is stated that some microbial methods are not able to distinguish between different antibiotic group 
but only detect growth inhibition in general. In case material C, containing lincomycin and 
spectinomycin, was reported negative this is considered a false negative result for both compounds. In 
case growth  inhibition was detected in this material, it was assumed correct for both lincomycin and 
spectinomycin. 
After the individual evaluation of the laboratories an overall evaluation was carried out. In this the 
overall false positive and false negative rate was calculated for all laboratories that send in results for 
the screening analysis [10]. Next it was studied if any relation exists between false negatives occurring 
and applied screening methods. 
4.2 Quantitative analysis 
For the evaluation of the quantitative results the assigend value, the uncertainty of the assigend value, a 
target standard deviation and z-scores were calculated. For the materials for which less than seven 
laboratories reported quantitative results, the data is not statistically evaluated.  
4.2.1 Calculation of the assigned value 
The assigned value (X) was determined using robust statistics [8,11,12]. The advantage of robust 
statistics is that all values are taken into account: outlying observations are retained, but given less 
weight. Furthermore, it is not expected to receive normally distributed data in a proficiency test. When 
using robust statistics, the data does not have to be normally distributed in contrast to conventional 
outlier elimination methods. 
The robust mean of the reported results of all participants, calculated from an iterative process that starts 
at the median of the reported results using a cut-off value depending on the number of results, was used 
as the assigned value [8,11]. The assigned value is therefore a consensus value. 
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 4.2.2 Calculation of the uncertainty of the assigned value 
The uncertainty of the assigned value is calculated to determine the influence of this uncertainty on the 
evaluation of the laboratories. A high uncertainty of the assigned value will lead to a high uncertainty of 
the calculated participants za-scores. If the uncertainty of the assigned value and thus the uncertainty of 
the za-score is high, the evaluation could indicate unsatisfactory method performance without any cause 
within the laboratory. In other words, illegitimate conclusions could be drawn regarding the 
performance of the participating laboratories from the calculated za-scores if the uncertainty of the 
assigned value is not taken into account. 
The uncertainty of the assigned value (the robust mean) is calculated from the estimate of the standard 
deviation of the assigned value and the number of values used for the calculation of the assigned value: 
 
n
σˆ
u =  
 
where: 
u = uncertainty of the assigned value;  
n = number of values used to calculate the assigned value;  
σˆ = The estimate of the standard deviation of the assigned value resulting from robust statistics. 
 
According to ISO/DIS 13528 [8] the uncertainty of the assigned value (u) is negligible and therefore 
does not have to be included in the statistical evaluation if: 
 
pσ3,0u ≤  
 
where: 
u = The uncertainty of the assigned value; 
p
σ = target standard deviation (§ 4.3). 
 
In case the uncertainty of the assigned value does not comply with this criterion, the uncertainty of the 
assigned value should be taken into account when evaluating the performance of the participants 
regarding the accuracy (§ 4.4). 
4.2.3 Calculation of the target standard deviation 
According to Commission Decision 2002/657/EC [13], the coefficient of variation for the repeated 
analysis of a reference or fortified material under reproducibility conditions, shall not exceed the level 
calculated by the Horwitz equation. The Horwitz equation, , presents a useful and 
widespread applied relation between the expected standard deviation of a singular analysis result under 
reproducibility conditions, and the concentration, c (g/g). It expresses inter-laboratory precision 
expected in inter-laboratory trials. Therefore, this relation is suitable for calculating the target standard 
deviation, in proficiency tests. 
8495.0
H c02.0σ =
Hσ
pσ
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 Thompson [7] demonstrated that the Horwitz equation is not applicable to the lower concentration range 
(<120 µg/kg) as well as to the higher concentration range (>138 g/kg). Therefore a complementary 
model is suggested: 
 
 
For analyte concentrations <120 µg/kg: 
c22.0σ H =  
 
For analyte concentrations >138 g/kg: 
5.0
H c01.0σ =  
 
where: 
Hσ = expected standard deviation in inter-laboratory trials; 
c  = concentration of the analyte (g/g). 
  
The target standard deviation ( ) of flumequine was determined using the regular Horwitz equation. In 
this calculation c = the assigned value (X) expressed in g/g and  
pσ
pH σσ = .
4.2.4 Performance characteristics with regard to the accuracy 
For illustrating the performance of the participating laboratories with regard to the accuracy a za-score is 
calculated. For the evaluation of the performance of the laboratories, the Guidelines of ISO/IEC Guide 
43-1 [3] and ISO/DIS 13528 [8] are applied. According to these guidelines za-scores are classified as 
presented in Table 4.  
Table 4: Classification of za-scores 
z ≤ 2 Satisfactory 
2 < z < 3 Questionable 
z ≥ 3 Unsatisfactory 
 
If the calculated uncertainty of the assigned value complies with the criterion mentioned in § 4.2.2, the 
uncertainty is negligible. In this case the accuracy z-score is calculated from: 
 
p
a σ
Xx
z
-
=  
 
where: 
az = accuracy z-score; 
x = the average result of the laboratory; 
X = assigned value; 
pσ = target standard deviation. 
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 However, if the uncertainty of the assigned value does not comply with the criterion mentioned in § 4.2, 
it could influence the evaluation of the laboratories. Therefore in this case, the uncertainty is taken into 
account by calculating the accuracy z-score [8]: 
 
22
p
a
uσ
Xx
'z
+
-
=   
 
where: 
a'z = accuracy z-score taking into account the uncertainty of the assigned value; 
x = the average result of the laboratory; 
X  = assigned value; 
pσ = target standard deviation; 
u  = uncertainty of the assigned value. 
 
If a consequential instability of the proficiency test materials exists, this can influence the evaluation of 
the laboratory performance. Therefore, in that case the consequential instability should be taken into 
account when calculating z-scores. If this is done, the absolute value of the z-scores will decrease. In 
this proficiency study no correction in z-scores was made for possible consequential instabilities, 
because all z-scores obtained indicated satisfactory performance already.  
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 5 Results and discussion 
Twenty-six laboratories subscribed for the participation in the proficiency test for antibiotics in beef.  
All laboratories managed to report their results within the timeframe of the study. Of these 23 
laboratories carried out a screening analysis and 19 carried out at least one confirmatory analysis (Table 
5). For laboratories that carried out a screening and a confirmatory analysis the choice of the applied 
confirmatory analysis was either based on the screening analysis results or many different confirmatory 
analysis were applied independent of the screening analysis results.  
Table 5. Amount of laboratories that reported results for each analysis. 
Analysis Compound No. of labs that reported a result 
Screening  23 
Total 19 
Flumequine 17 
Lincomycin 7 
Quantitative / confirmatory 
Spectinomycin 4 
5.1 Evaluation of the screening analysis 
In the ideal case each laboratory that carried out a screening analysis would find the sample of material 
A compliant, the sample of material B and C suspect (respectively for quinolones and 
lincomycin/spectinomycin). The actual screening results are presented in Annex 7a. 
 
In this proficiency test for the screening analysis five false positive results (7%) and 34 false negative 
results (53%) occurred. For flumequine of the 22 labs that have flumequine included in their method 14 
reported material B as a suspect sample for either flumequine, quinolones or a growth inhibitor (32% 
false negative). For lincomycin of the 20 labs that have lincomycin included in their method nine 
reported material C as a suspect sample for either lincomycin, macrolides or a growth inhibitor (55% 
false negatives). For spectinomycin of the 17 labs that have spectinomycin included in their method six 
reported material C as a suspect sample for either spectinomycin, aminoglycosides or a growth inhibitor 
(65% false negatives). It is stated that some laboratories applied multiple methods for the screening 
analysis. 
 
The false negative rate (not detected but included in the method) for the microbiological methods is 
73%, for biochemical methods 50% and for instrumental screening methods 22%.  
 
For flumequine it stands out that the false negative results mainly occurred for laboratories that relied on 
a microbiological screening method. It can be concluded that an E. coli plate at pH=8 is not suited for 
the screening of bovine muscle on the presence of flumequine at relevant levels. The Nouws Antibiotic 
Test (NAT, 5-plate test) correctly indicated the presence of quinolones in material B. Also one of the 
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 laboratories (lab 6) reported a suspect Premi-test result for material B, but in this case also the blank 
material was reported suspect. 
 
Lincomycin in material C is only detected by instrumental methods, the microbiological NAT as applied 
by laboratory 4 and 7 and the Premi-test after solvent extraction as applied by lab 10. Also laboratory 6 
reported the presence of a growth inhibitor in the sample of material C using the Premi-test but this 
laboratory also assigned material A as suspect (false positive). Other laboratories using the Premi-test 
did not find material C suspect. Also the EU four plate test appears incapable of detecting the antibiotic 
combination in material C. The same accounts for the biochemical Charm II test, although it should 
respond to macrolides and lincosamines.  
It is concluded that only instrumental methods, the NAT and the Premi-test after solvent extraction are 
suited for the screening analysis of lincomycin at relevant levels. 
 
Spectinomycin is only detected by instrumental screening methods. Laboratory 6 reported the presence 
of a growth inhibitor in the sample of material C using the Premi-test but this laboratory also reported 
growth inhibition for material A and other laboratories using the Premi-test did not find material C 
suspect. The biochemical Charm II test did not detect spectinomycin, because it responds to 
streptomycins only. It is concluded that none of the applied microbiological or biochemical methods is 
able to detect spectinomycin at the level chosen in this proficiency test. 
 
Using instrumental screening methods four false negative results were reported. One was obtained using 
a targeted method (lab 18, LC-DAD and LC-FLD) and three using non-targeted analysis (lab 19 and 21, 
LC-ToF/MS). For screening analysis using targeted methods it is of importance that all relevant 
compounds are included. Flumequine was not included by one laboratory, lincomycin by three 
laboratories and spiramycin by two laboratories that carried out an instrumental screening analysis for 
the corresponding antibiotic group.  
5.2 Evaluation of the quantitative analysis 
Nineteen laboratories carried out one or more quantitative confirmatory analyses. An overview of the 
compounds found in the samples by the participating laboratories is presented in Annex 8a. Annex 8b 
gives an overview of false positive results that occurred for the quantitative analysis. One laboratory 
(Lab 1) reported sulfamethazine with an amount of 25 µg/kg in the sample belonging to material C. This 
is considered as a false positive result. No false negative results occurred. 
 
Nineteen laboratories carried out a quantitative confirmatory analysis for flumequine. All of these 
laboratories confirmed the presence of flumequine and reported a quantitative result (Annex 9). The 
lowest value reported is 209.3 µg/kg and the highest value is 342 µg/kg. The assigned value of 
flumequine is 267.2 µg/kg with an uncertainty of 7.6 µg/kg. The uncertainty of the assigned value does 
not exceeds 0.3σp (§4.2), therefore the uncertainty of the assigned value is not taken into account in the 
evaluation of the laboratories. The za-scores obtained by each laboratory were calculated (Annex 9, a 
graphical representation of the za-scores is included). With respect to the accuracy all results are 
satisfactory.  
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 Seven laboratories carried out a quantitative confirmatory analysis for lincomycin. All of these 
laboratories confirmed the presence of lincomycin and reported a quantitative result (Annex 10). The 
lowest value reported is 90 µg/kg and the highest value is 118 µg/kg. The assigned value of lincomycin 
is 111.7 µg/kg with an uncertainty of 2.5 µg/kg. The uncertainty of the assigned value does exceeds 
0.3σp (§4.2), therefore the uncertainty of the assigned value is taken into account in the evaluation of the 
laboratories. The z'a-scores obtained by each laboratory were calculated (Annex 10, a graphical 
representation of the z'a-scores is included). With respect to the accuracy all results are satisfactory. 
 
Four laboratories carried out a quantitative/confirmatory analysis for spectinomycin. All of these 
laboratories confirmed the presence of spectinomycin and reported a quantitative result. The lowest 
value reported is 128 µg/kg and the highest value is 390 µg/kg. Because only four results are reported, 
no statistical evaluation is carried out.  
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 6 Conclusions 
All of the 26 participating laboratories reported results for the proficiency study of antibiotics in beef. In 
this three laboratories showed optimal performance by detecting all compounds, the absence of false 
positives and false negatives and a correct quantification of flumequine and lincomycin.  
 
For the screening analysis a high percentage (53%) of false negatives occurred. For the microbiological 
methods the total false negative rate is 73%, for biochemical tests this is 50% and for instrumental 
methods this is 22%. The high false negative rate for microbiological and biochemical methods is 
mainly due to the use of E. coli plates at pH=8 for the screening of quinolones giving a negative result 
for flumequine and to the use of microbiological and biochemical methods that are not able to detect 
lincomycin and/or spectinomycin.  
 
For the quantitative and confirmatory analysis 17 laboratories reported results for flumequine, seven for 
lincomycin and four for spectinomycin. For flumequine and lincomycin a statistical evaluation was 
carried out. For spectinomycin the number of results is too low to draw statistically significant 
conclusions. For flumequin all laboratories obtained a za-score between -1.08 and 1.47 meaning that the 
performance for the quantitative analysis of flumequine is satisfactory for all laboratories. For 
lincomycin all laboratories obtained a z'a-score between -0.88 and 0.26 meaning that the performance 
for the quantitative analysis of lincomycin is satisfactory for all laboratories. 
 
Based on the results of this proficiency test it is concluded that: 
• a huge effort is needed to improve the effectiveness and efficiency for the analyses of unknown 
samples; 
• a huge effort is needed to decrease the false negative rate of mainly microbiological screening 
methods; 
• for effectively applying instrumental screening methods (LC-MS/MS or LC-ToF MS) an effort is 
needed to include a much wider range of compounds; 
• the laboratories performance regarding the quantitative analysis of flumequine and lincomycin in 
beef is satisfactory. 
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 Annex 1 Codification of the samples 
Sample set no. Material A* Material B* Material C* 
1 032 145 160 
2 078 004 200 
3 175 083 197 
4 043 105 071 
5 188 140 183 
6 059 082 177 
7 185 161 228 
8 041 023 135 
9 132 052 235 
10 214 172 084 
11 147 158 211 
12 053 182 226 
13 002 232 065 
14 215 116 019 
15 204 238 067 
16 144 031 122 
17 077 162 164 
18 184 006 206 
19 060 213 141 
20 010 236 186 
21 088 119 180 
22 094 165 221 
23 223 069 093 
24 014 035 202 
25 174 027 210 
26 229 133 201 
* all sample codes start with AB1/2009/MUSCLE/ 
RIKILT Report 2009.015 21
 Annex 2a Statistical evaluation of homogeneity data of material 
B for flumequine 
 Flumequine (µg/kg) 
Sample No. Replicate 1 Replicate 2 
062 403.4 421.7 
086 394.2 388.7 
091 441.8 407.1 
117 460.9 455.8 
150 403.1 398.4 
151 396.3 421.6 
171 412.4 412.0 
178 442.9 367.6 
199 439.6 386.4 
222 441.6 432.9 
Grand mean 415.4 
Cochran’s test   
C 0.372 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s =  Hσ Horwitz: 75.9  
sx 20.2 
sw 20.3 
ss 14.2 
Critical = 0.3  Hσ 22.8 
ss < critical? ACCEPTED 
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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 Annex 2b Statistical evaluation of homogeneity data of material 
C for lincomycin 
 Lincomycin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
15 117.6 123.8 
42 122.2 117.9 
50 118.8 123.5 
97 113.2 119.1 
98 127.0 121.6 
125 122.0 119.5 
195 126.5 122.0 
218 121.4 118.2 
224 121.9 123.7 
230 117.8 129.7 
Grand mean 121.4 
Cochran’s test   
C 0.436 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s =  Hσ Horwitz: 26.7  
sx 2.5 
sw 4.0 
ss 0.0 
Critical = 0.3  Hσ 8.0 
ss < critical? ACCEPTED 
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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 Annex 2c Statistical evaluation of homogeneity data of material 
C for spectinomycin 
 Spectinomycin (µg/kg) 
Sample No. Replicate 1 Replicate 2 
15 195.0 215.2 
42 235.5 223.1 
50 231.7 199.7 
97 229.6 185.9 
98 250.2 229.9 
125 193.1 238.0 
195 231.2 221.8 
218 217.4 223.7 
224 209.9 188.8 
230 209.5 181.9 
Grand mean 215.6 
Cochran’s test   
C 0.278 
Ccrit 0.602 
C < Ccrit? NO OUTLIERS 
Target s =  Hσ Horwitz: 43.5 
sx 14.0 
sw 19.1 
ss 3.8 
Critical = 0.3  Hσ 13.0 
ss < critical? ACCEPTED 
 
sx = standard deviation of the sample averages 
sw = within-sample standard deviation 
ss = between-sample standard deviation  
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 Annex 7a Overview of screening results 
Lab Material A Material B Material C 
2 - Quinolones - 
3 - Flumequine Lincomycin 
4 - Quinolones Macrolide 
6 Growth inhibitor Growth inhibitor Growth inhibitor 
7 - Quinolones Macrolide 
8 Macrolide Macrolide - 
9 - - - 
10 - Flumequine Growth inhibitor 
11 - - - 
12 - - - 
13 - Flumequine 
Lincomycin 
Spectinomycin 
14 - Quinolones - 
15 
ß-lactam 
Macrolide 
- - 
16 - - - 
17 - Flumequine - 
18 - - - 
19 - Flumequine Spectinomycin 
20 - - - 
21 - Flumequine - 
22 - Flumequine 
Lincomycin 
Spectinomycin 
24 - Flumequine Lincomycin 
25 - Flumequine 
Lincomycin 
Spectinomycin 
- = not detected 
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 Annex 7b False positives and false negatives in screening analysis 
False positive results 
Lab code Sample code Material Suspect for 
6 059 A Growth inhibitor
8 041 A Macrolides 
8 023 B Macrolides 
15 204 A ß-lactams 
15 204 A Macrolides 
 
 
False negative results 
Lab code Sample code Flumequine Sample code Lincomycin Spectinomycin 
2   200 X X* 
3   197  X* 
4   071  X 
7   228  X 
8 023 X 135 X X 
9 052 X* 235 X* X* 
11 158 X 211 X X 
12 182 X 226 X X 
14   019 X X* 
15 238 X 067 X X 
16 031 X 122 X X 
17   164 X X 
18 006 X 206 X* X* 
19   141 X*  
20 236 X 186 X X 
21   180 X X 
24   202  X 
X = Not detected 
* not included in the analysis 
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 Annex 8a Overview of quantitative/confirmatory results 
Lab Material A Material B Material C 
1  Flumequine Sulfamethazine 
2  Flumequine  
3  Flumequine Lincomycin 
4  Flumequine Lincomycin 
5    
7  Flumequine Lincomycin 
8  Flumequine  
10  Flumequine  
11  Flumequine  
13  Flumequine 
Lincomycin, 
Spectinomycin 
14  Flumequine  
17  Flumequine  
19  Flumequine Spectinomycin 
20  Flumequine Lincomycin 
21  Flumequine  
22  Flumequine 
Lincomycin 
Spectinomycin 
23  Flumequine  
25  Flumequine 
Lincomycin 
Spectinomycin 
26    
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Annex 8b False positives and false negatives in 
quantitative/confirmatory analysis 
False positive results 
Lab code Sample code Material Compound confirmed 
1 160 C Sulfamethazine 
 
 
False negative results 
None 
 Annex 9 Results for the analysis of flumequine 
Flumequine 
Assigned value: 267.2 µg/kg 
Uncertainty of assigned value: 7.6 µg/kg 
Target standard deviation (Horwitz, Thompson):  52.1 µg/kg 
Lab code Result (µg/kg) za-score 
1 342 1,43
2 266 -0,02
3 285 0,34
4 300,1 0,63
7 320 1,01
8 209,3 -1,11
10 276 0,17
11 269 0,03
13 218 -0,94
14 290 0,44
17 239 -0,54
19 210 -1,10
20 250 -0,33
21 250 -0,33
22 260 -0,14
23 278 0,21
25 276 0,17
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Annex 9 continued     Results for the analysis of flumequine 
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Figure a: Graphical representation of the reported results 
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Figure b: Graphical representation of z-scores        
 Annex 10 Results for the analysis of lincomycin 
Lincomycin 
Assigned value: 111.7 µg/kg 
Uncertainty of assigned value: 2.46 µg/kg 
Target standard deviation (Horwitz, Thompson):  24.6 µg/kg 
Lab code Result (µg/kg) z'a-score 
3 90 -0,88
4 117,3 0,23
7 114 0,09
13 115 0,14
20 118 0,26
22 104 -0,31
25 105 -0,27
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Annex 10 continued     Results for the analysis of lincomycin 
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Figure a: Graphical representation of the reported results 
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 Annex 11 Results for the analysis of spectinomycin 
 Spectinomycin 
Lab code Result (µg/kg) 
13 163 
19 210 
22 390 
25 128 
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